Stifel has designated DexCom as its top investment idea in the medical technology and supplies category, citing the continuous glucose monitor maker's robust second-quarter 2026 performance and an encouraging forward view.
The investment bank's assessment follows a quarter in which DexCom exceeded consensus on multiple fronts. According to Stifel, the company outperformed expectations for revenue, gross margin, operating margin and earnings per share, prompting the firm to raise its 2026 guidance for both organic revenue growth and margin metrics.
Quarterly performance and analyst reaction
DexCom reported second-quarter revenue of $1.308 billion, representing a 12% year-over-year organic increase and topping estimates. In the wake of the results, a number of analysts, including RBC Capital, BTIG and Truist Securities, revised their price targets higher for the company.
Market share and strategic positioning
Management commentary about gains in market share aligns with Stifel's recent survey findings. Stifel interprets this alignment as evidence that DexCom has secured long-term U.S. share gains for the first time in years - a development the firm views as meaningful for the company's competitive standing.
Drivers of future growth
Stifel highlighted several pathways that could sustain DexCom's momentum. The firm points to the upcoming Type 2 non-insulin treated diabetes opportunity, which Stifel says remains on track for year-end 2026 with coverage anticipated by mid-2027. In addition, the company is expected to derive early-stage growth from its 15-Day product, further international expansion and a multi-year plan to expand gross margins.
The margin expansion timetable described by Stifel includes U.S. benefits from the 15-Day product in 2026 and 2027, international 15-Day contributions in 2027 and 2028, and the introduction of the G8 product starting in 2028 and thereafter.
Financial modeling and valuation
Reflecting these inputs, Stifel raised its estimates for 2026 through 2028 and established a price target of $95 per share. The firm also noted that despite a rally in DexCom shares since the company's mid-May Investor Day, it sees multiple avenues for continued upside tied to product rollouts and market penetration.
Outlook
Stifel's view positions DexCom as well-placed to capitalize on near-term and multi-year growth drivers, contingent on the timing and execution of product launches, international uptake and payer coverage for new indications.
Key points
- Stifel names DexCom its top pick in medical technology and supplies after Q2 2026 results beat expectations across revenue, margins and EPS.
- Management commentary and Stifel survey data suggest DexCom achieved long-term U.S. share gains for the first time in years, supporting a more optimistic outlook.
- Primary catalysts include the 15-Day product, international expansion and the Type 2 non-insulin treated diabetes market opportunity, with multi-year margin expansion expected as products scale.
Risks and uncertainties
- Timing and extent of payer coverage for the Type 2 non-insulin treated diabetes indication - Stifel notes coverage is expected by mid-2027 but the outcome and timing remain material to revenue realization.
- Execution of product rollouts and margin expansion - projected benefits from the U.S. 15-Day product, international 15-Day adoption and the G8 launch are phased across 2026-2028 and beyond, creating execution risk tied to those timelines.
- Competitive dynamics in the diabetes management market - the firm highlighted DexCom's progress in a competitive market, implying that continued gains are subject to competitive response.
Tags: medtech, healthcare, diabetes, DXCM